Literature DB >> 34611292

Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?

Thomas Millard1, Fatin Sammour1, Chloe Anthias1,2,3, Sandra Easdale1, Carlos Gonzalez-Arias1, Mark Ethell1, Mike Potter1, Sunil Iyengar1,2, Dima El-Sharkawi1,2, Ayoma D Attygalle1, Ian Chau1,2, David Cunningham1,2, Emma Nicholson1, Bhupinder Sharma4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34611292     DOI： 10.1038/s41409-021-01484-7

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors-early experience.

Authors:  Winnie Wing-Chuen Lam; David Chee-Eng Ng; Wai Yin Wong; Seng Chuan Ong; Sidney Wing-Kwong Yu; Siew Ju See
Journal:  Clin Neurol Neurosurg       Date:  2010-10-30       Impact factor: 1.876

2.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Authors:  Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

3.  Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

Authors:  Craig S Sauter; Matthew J Matasar; Jessica Meikle; Heiko Schoder; Gary A Ulaner; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Andrew D Zelenetz; Craig H Moskowitz
Journal:  Blood       Date:  2015-03-10       Impact factor: 22.113

4.  Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.

Authors:  Christopher P Fox; Elizabeth H Phillips; Jeffery Smith; Kim Linton; Eve Gallop-Evans; Claire Hemmaway; Dorothee P Auer; Charlotte Fuller; Andrew J Davies; Pamela McKay; Kate Cwynarski
Journal:  Br J Haematol       Date:  2018-11-23       Impact factor: 6.998

Review 5.  Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis.

Authors:  Anca Prica; Kelvin Chan; Matthew C Cheung
Journal:  Br J Haematol       Date:  2012-06-26       Impact factor: 6.998

6.  Evolution of lymphoma staging and response evaluation: current limitations and future directions.

Authors:  Joel Cunningham; Sunil Iyengar; Bhupinder Sharma
Journal:  Nat Rev Clin Oncol       Date:  2017-06-13       Impact factor: 66.675

Review 7.  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Authors:  Bruce D Cheson; Stephen Ansell; Larry Schwartz; Leo I Gordon; Ranjana Advani; Heather A Jacene; Axel Hoos; Sally F Barrington; Philippe Armand
Journal:  Blood       Date:  2016-08-29       Impact factor: 22.113

Review 8.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

9.  Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Christopher P Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Peter Johnson; Kim M Linton; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; Stefan W Krause; Hans J Schmoll; Bernd Hertenstein; Mathias Rummel; Jeffery Smith; Michael Pfreundschuh; Giuseppina Cabras; Francesco Angrilli; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Jürgen Finke; Michele Reni; Franco Cavalli; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2017-10-17       Impact factor: 18.959

10.  MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.

Authors:  J Xiong; L Wang; X-C Fei; X-F Jiang; Z Zheng; Y Zhao; C-F Wang; B Li; S-J Chen; A Janin; R P Gale; W-L Zhao
Journal:  Blood Cancer J       Date:  2017-07-07       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.